Most patients with pancreatic ductal adenocarcinoma (PDAC) present with symptomatic,
surgically unresectable disease. Although the goal of early detection of PDAC is laudable …

The management of intraductal papillary mucinous neoplasm (IPMN) continues to evolve. In
particular, the indications for resection of branch duct IPMN have changed from early …

Evidence-based guidelines on the management of pancreatic cystic neoplasms (PCN) are
lacking. This guideline is a joint initiative of the European Study Group on Cystic Tumours of …

Objective DNA-based testing of pancreatic cyst fluid (PCF) is a useful adjunct to the
evaluation of pancreatic cysts (PCs). Mutations in KRAS/GNAS are highly specific for …

Pancreatic cystic neoplasms (PCN) are a heterogeneous group of pancreatic cysts that
include intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, serous cystic …

For cancer screening to be successful, it should primarily detect cancers with lethal potential
or their precursors early, leading to therapy that reduces mortality and morbidity. Screening …

Background & Aims Next-generation sequencing (NGS) of pancreatic cyst fluid is a useful
adjunct in the assessment of patients with pancreatic cyst. However, previous studies have …

This study group aimed to revise the 2017 international consensus guidelines for the
management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas, and …

Despite considerable research efforts, pancreatic cancer is associated with a dire prognosis
and a 5-year survival rate of only 10%. Early symptoms of the disease are mostly …

Due to its poor prognosis and the late stage at which it is typically diagnosed, early detection
of pancreatic cancer is a pressing clinical problem. Advances in genomic analysis of human …